OBJECTIVE
 Symptoms of BPH begin to appear as early as age 40 years. An estimated 50% men have BPH by the age of 60 years and 90% men by 85 years. 2  Tadalafil, an oral, potent selective phosphodiesterase type 5 inhibitor, is approved for the treatment of BPH in men with/without erectile dysfunction (ED). 3, 4  To the best of our knowledge, no systematic review has evaluated the adverse events (AEs) associated with use of tadalafil in clinical trials.
 As compared to placebo, tadalafil was associated with a significantly higher incidence of all analyzed AEs except nasopharyngitis ( Fig. 2)  PubMed, EMBASE, Cochrane Library, and Google Scholar databases were searched, from inception to August 2014, for RCTs comparing tadalafil with placebo or active comparators for the treatment of BPH with/without ED.
 Search terms included "Benign prostatic hyperplasia," "benign enlargement of prostate," "adenofibromyomatous hyperplasia," benign prostatic hypertrophy," "lower urinary tract symptom," and "tadalafil."
 The selection of study for inclusion was based on a pre-specified protocol with the following inclusion criteria:
 Population: Adults (aged ≥40) with BPH as defined by International prostate symptom score or maximum urinary flow rate
• Exclusion criteria were suspected or confirmed prostate cancer, surgery of the prostate, urethra and bladder.
 Intervention: Tadalafil (5 mg/day) as a single therapy  Comparators: Placebo or any approved intervention for BPH  Outcomes: Any AE  All retrieved articles were assessed for the inclusion or exclusion by two independent reviewer, and discrepancies between them were resolved through discussion.
 Two independent reviewer extracted the data (including study sample size, AEs, withdrawals due to AEs etc.) in a customized spreadsheet; any disagreement was resolved by a third independent reviewer.
 Cochrane risk bias assessment tool was used to assess bias.
 Data analysis: descriptive and quantitative data synthesis was performed for AEs when appropriate. Meta-analysis was performed using STATA ® SE11.2 and results were presented as risk ratios (RR) and associated 95% confidence interval (CI).
 This systematic review and meta analysis of RCTs suggested that tadalafil is a safe option when used in BPH patients at the approved dose without any concerning AE.
 Direct meta-analysis comparing tadalafil to other approved BPH interventions, except tamsulosin, was not possible due to lack of head-to-head RCTs. Further analysis using indirect or mixed treatment studies is warranted.  The risk of bias was low across the included studies.
 In 7 studies, tadalafil was compared with placebo. In 3 studies, it was compared with tamsulosin along with placebo ( Table 1) .  Significant differences were not observed for incidence of any of the AEs between monotherapy of tadalafil and tamsulosin (0.2-0.4 mg/day) (Fig. 3) . 
